Atlas Trials

Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

Clinical trial NCT01342172 · TERMINATED

Trial details

NCT number
NCT01342172
Sponsor
Icahn School of Medicine at Mount Sinai
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Urinary Bladder Neoplasms
Start date
2011-03-01
Primary completion
2013-06-01
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.